Finally, it has been shown that simvastatin can inhibit the HIF-1α/PPARγ/PKM2 axis, suppressing PKM2-mediated glycolysis, decreasing cell proliferation, and increasing the expression of apoptotic markers in HCC cells, sensitizing of them to sorafenib treatment [112]. The gene discussed is PKM; the disease is hepatocellular carcinoma.